Homepage Top Section1

After granting priority review for the application, the FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of 5 August 2023. The drug is being evaluated

The optogenetic monotherapy has been developed to restore vision in blind patients. Nanoscope CEO Sulagna Bhattacharya said: “We are pleased to receive the FDA’s decision to grant Fast

Under the terms of the partnership deal between the companies, Hyloris will receive a share on any revenues related to product, such as royalties, license fees, milestone payments,

The recombinant adeno-associated virus (rAAV)-based gene therapy is being studied to treat neovascular Age Related Macular Degeneration (nAMD), which causes severe loss of vision and irreversible blindness across

The inhaled mRNA-based therapeutic is intended for people with CF, including those with genotypes that are not responsive to approved CFTR modulators. ReCode Therapeutics CEO Shehnaaz Suliman said:

As per the terms of the agreement, Spruce will get an upfront payment of $15m from Kaken. It will also be eligible to get further payments following the

Innovate UK awarded the grant as part of its Biomedical Catalyst 2022 research and development (R&D) competition. Alchemab is currently undertaking the preclinical studies to progress its antibodies

Darovasertib is a potential first-in-class protein kinase C (PKC) inhibitor, and crizotinib is an investigational cMET inhibitor. The designation will allow the darovasertib / crizotinib development programme to

Curevo Vaccine CEO George Simeon said: “Completing this A1 round ahead of data from our Phase 2b trial of CRV-101 head-to-head against Shingrix is a meaningful demonstration of